Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and ...

The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below ...

Biotech investing can feel a little bit like a Vegas sportsbook sometimes. Pick the company with the right drug trial and you ...

The State Street SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. What Are ...

Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say “some investors” because, it turns out, not all biotech ETFs are created equal. In our 2012 ...

Discover why State Street SPDR S&P Biotech ETF (XBI) is up 30% YTD, its unique high-beta structure, and key risks for biotech investors.

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ...

These low-cost funds offer broad diversification across key market segments, which have driven wealth creation for years.

So, history shows us that investing in the S&P 500 at a high will lead to declines -- but there's some positive news here too ...

LifeSci Partners, LLC launched two new ETFs that concentrate on one of the most popular sectors in the market. The New York-based investment advisor launched the BioShares Biotechnology Clinical ...